The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

Ertugliflozin has also been approved in combination with metformin under the brand name ... ="202"] Jardiance is setting the pace among SGLT2 inhibitors[/caption] There is a crowd of already ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

with metformin in 2,500 patients in four trials, and with piogliltazone in 1,500 subjects in four trials. This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects ...